Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hematology

Hemophilia B: Biology, Genetics, and Diagnosis

At a Glance

Hemophilia B is an inherited bleeding disorder caused by a deficiency in the Factor IX protein. Severity depends on your specific factor levels. It is critical that your care team uses the correct lab test, such as a chromogenic assay, validated for your specific medication to ensure proper dosing.

Learning that you or your child has Hemophilia B can feel like entering a new world filled with complex science and unfamiliar terms. It is natural to feel overwhelmed, but understanding the biological foundation of this condition is the first step toward confident management. Hemophilia B is a lifelong bleeding disorder that occurs when the body does not produce enough Factor IX (FIX), a protein essential for blood clotting [1][2].

The Genetics of Hemophilia B

Hemophilia B is caused by changes, or variants, in the F9 gene [3]. This gene provides the “blueprints” for making the Factor IX protein. The condition follows an X-linked recessive inheritance pattern, which explains why it primarily affects males:

  • Chromosomes: Males have one X and one Y chromosome; females have two X chromosomes.
  • Inheritance: Because the F9 gene is on the X chromosome, a male who inherits an X chromosome with a variant will have Hemophilia B [1]. A female with a variant on one of her two X chromosomes is known as a carrier.
  • Spontaneous Variants: In about one-third of cases, Hemophilia B occurs even when there is no family history, caused by a new (spontaneous) genetic change [4].

A Note on Female Carriers and Mild Hemophilia:
Historically, it was believed that female carriers did not experience symptoms. We now know that many women have Factor IX levels low enough to cause serious bleeding issues, such as heavy menstrual periods or bruising [5][3]. Thanks to updated medical guidelines, women and girls with Factor IX levels below 40% are now formally diagnosed with Mild Hemophilia B rather than just being called “symptomatic carriers.” This validates their bleeding symptoms and ensures they receive standard hemophilia care [3].

Because this is a genetic condition, genetic counseling is highly recommended. A genetic counselor can help you understand how the F9 gene affects your specific family tree, how to interpret your mutation, and when to test siblings or future children.

How Common is Hemophilia B?

Hemophilia B is rarer than Hemophilia A. Large-scale studies show that it occurs in approximately 5 out of every 100,000 male births [6]. Worldwide, it is estimated that over 1.1 million people are living with some form of hemophilia [6].

Defining Severity Levels

The “severity” of Hemophilia B is determined by the amount of Factor IX activity in the blood. In people without hemophilia, normal levels range from 50% to 150% [7].

Category Factor IX Activity Level Clinical Impact
Severe Less than 1% (<1 IU/dL) Frequent spontaneous bleeding into joints or muscles. [7]
Moderate 1% to 5% (1–5 IU/dL) Bleeding usually follows minor trauma; occasional spontaneous bleeds. [8]
Mild 5% to 40% (5–40 IU/dL) Bleeding typically occurs only after surgery or major injury. [9]

The Challenges of Diagnosis and Testing

Diagnosing Hemophilia B involves measuring the aPTT (activated partial thromboplastin time), which tells doctors how long it takes for your blood to clot, followed by a specific Factor IX activity assay to confirm the deficiency [10][11].

However, not all laboratory tests are the same, and this is where patients must be vigilant. There are two main types of tests:

  1. One-Stage Clotting Assay (OSA): The traditional, most common test [12].
  2. Chromogenic Substrate Assay (CSA): A newer method that measures the chemical reaction of the factor directly [13].

The “Assay Discrepancy” Warning

If you are treated with newer Extended Half-Life (EHL) products—medications designed to last longer in the body—the OSA and CSA tests can give very different results [14][15]. For example, a one-stage test might show your factor level is 30%, while a chromogenic test shows it is actually 15% [16].

This assay discrepancy happens because the chemical markers used in some tests don’t “react” correctly with the modified EHL proteins [12][15]. To ensure your dose is correct, your medical team must use a lab test that is specifically validated for the exact brand of Factor IX you are using [17][18]. Always ask your doctor which test they are using to monitor your levels.

Common questions in this guide

Can females get Hemophilia B?
Yes. While historically called asymptomatic carriers, many women and girls with an F9 gene variant have Factor IX levels low enough to cause serious bleeding, like heavy periods. Those with levels below 40% are formally diagnosed with Mild Hemophilia B.
What does assay discrepancy mean in Hemophilia B testing?
An assay discrepancy happens when different types of lab tests produce conflicting Factor IX levels. This is especially common if you use extended half-life (EHL) treatments, as older tests may not measure these modified proteins accurately.
How is the severity of Hemophilia B determined?
Severity is based on the percentage of Factor IX activity in your blood. Severe Hemophilia B means levels are less than 1%, moderate is between 1% and 5%, and mild is between 5% and 40%.
Why is genetic counseling recommended for Hemophilia B?
Since Hemophilia B is passed down through families on the X chromosome, a counselor helps you understand how the F9 gene affects your family tree. They can interpret genetic mutations and advise on testing for siblings or future children.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my (or my child's) exact Factor IX activity level and which severity category does it fall into?
  2. 2.Which specific laboratory assay—one-stage or chromogenic—does this hospital use to measure my factor levels?
  3. 3.If we switch to an extended half-life (EHL) product, does this lab have the correct reagents to measure it accurately?
  4. 4.Based on my family history, should my female relatives have their Factor IX levels and bleeding history assessed?
  5. 5.What is the specific F9 gene variant in our family, and what does that mean for future symptoms?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    The Clinical Genetics of Hemophilia B (Factor IX Deficiency).

    Miller CH

    The application of clinical genetics 2021; (14()):445-454 doi:10.2147/TACG.S288256.

    PMID: 34848993
  2. 2

    Molecular pathogenesis of a novel Met394Thr variant causing hemophilia B.

    Lu L, Wang L, Shen W, et al.

    Molecular genetics & genomic medicine 2023; (11(5)):e2147 doi:10.1002/mgg3.2147.

    PMID: 36795372
  3. 3

    Molecular characterization of hemophilia B patients in Colombia.

    Parrado Jara YA, Yunis Hazbun LK, Linares A, Yunis Londoño JJ

    Molecular genetics & genomic medicine 2020; (8(5)):e1210 doi:10.1002/mgg3.1210.

    PMID: 32155688
  4. 4

    Molecular analysis of 76 Chinese hemophilia B pedigrees and the identification of 10 novel mutations.

    Huang L, Li L, Lin S, et al.

    Molecular genetics & genomic medicine 2020; (8(11)):e1482 doi:10.1002/mgg3.1482.

    PMID: 32875744
  5. 5

    The spectrum of bleeding in women and girls with haemophilia B.

    Staber J, Croteau SE, Davis J, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2018; (24(2)):180-185 doi:10.1111/hae.13376.

    PMID: 29178325
  6. 6

    Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries.

    Iorio A, Stonebraker JS, Chambost H, et al.

    Annals of internal medicine 2019; (171(8)):540-546 doi:10.7326/M19-1208.

    PMID: 31499529
  7. 7

    Retrospective analysis of hemophilia B in Turkey: identifying main characteristics and treatment options.

    Zülfikar B, Koç B, Şahin F, et al.

    Research and practice in thrombosis and haemostasis 2024; (8(7)):102588 doi:10.1016/j.rpth.2024.102588.

    PMID: 39582809
  8. 8

    Fidanacogene Elaparvovec: First Approval.

    Dhillon S

    Drugs 2024; (84(4)):479-486 doi:10.1007/s40265-024-02017-4.

    PMID: 38472707
  9. 9

    Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series.

    Nagao A, Bingo M, Yamaguchi T, Fukutake K

    Cureus 2023; (15(1)):e33573 doi:10.7759/cureus.33573.

    PMID: 36779089
  10. 10

    Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.

    Zwagemaker AF, Kloosterman FR, Gouw SC, et al.

    Journal of thrombosis and haemostasis : JTH 2023; (21(4)):850-861 doi:10.1016/j.jtha.2022.11.040.

    PMID: 36696222
  11. 11

    Evaluation of discrepancy between clot-based and chromogenic factor IX coagulation assays in non-severe hemophilia B patients and identification of the causing mutations.

    Mahdavimand M, Tabibian S, Zafarani A, et al.

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2025; (64(1)):104063 doi:10.1016/j.transci.2024.104063.

    PMID: 39729820
  12. 12

    Recombinant FIX Fc fusion protein activity assessment with the one-stage clotting assay: A multicenter, assessor-blinded, prospective study in Japan (J-Field Study).

    Fukutake K, Kobayashi T, Sommer JM, Hirakata T

    International journal of laboratory hematology 2020; (42(2)):162-169 doi:10.1111/ijlh.13133.

    PMID: 31820573
  13. 13

    Performance of factor IX extended half-life product measurements in external quality control assessment programs.

    Nederlof A, Kitchen S, Meijer P, et al.

    Journal of thrombosis and haemostasis : JTH 2020; (18(8)):1874-1883 doi:10.1111/jth.14847.

    PMID: 32311825
  14. 14

    Drug-Specific Calibration: A Solution to Reagent Variability in Extended Half-Life Factor IX Activity Measurements.

    Grand F, Blanc-Jouvan F, Mourey G, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2025; (31(6)):1307-1314 doi:10.1111/hae.70115.

    PMID: 40898782
  15. 15

    Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy.

    Astermark J, Miesbach W, Coppens M, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2025; (31(4)):799-806 doi:10.1111/hae.70053.

    PMID: 40534246
  16. 16

    Clinical Implications of Discrepancy between One-Stage Clotting and Chromogenic Factor IX Activity in Hemophilia B.

    Schmidt DE, Truedsson Å, Strålfors A, et al.

    Thrombosis and haemostasis 2024; (124(1)):32-39 doi:10.1055/a-2142-0262.

    PMID: 37494968
  17. 17

    Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).

    Jeanpierre E, Pouplard C, Lasne D, et al.

    European journal of haematology 2020; (105(2)):103-115 doi:10.1111/ejh.13423.

    PMID: 32277501
  18. 18

    Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.

    Tiefenbacher S, Bohra R, Amiral J, et al.

    Journal of thrombosis and haemostasis : JTH 2017; (15(10)):1901-1912 doi:10.1111/jth.13787.

    PMID: 28772338

This page provides educational information about Hemophilia B genetics and diagnostics. Always consult your hematologist to interpret your specific factor levels and determine the right lab tests for your treatment plan.

Get notified when new evidence is published on Hemophilia B.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.